59 episodes

"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.

Not So Different: a Podcast from The Center for Biosimilars Not So Different: a Podcast from The Center for Biosimilars

    • Health & Fitness

"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.

    What European Markets Lack in Biosimilar Competition?

    What European Markets Lack in Biosimilar Competition?

    A market’s structure and incentives are critical in ensuring that companies that develop medications like biosimilars have a competitive environment to thrive. Several countries in Europe implement tender systems, which are used to limit which brand name products get a piece of the market share pie and often discourages unsuccessful competitors from contending in the future.  However, 2 representatives from Medicines for Europe designed a scorecard of European markets to show which ones are robust and competitive and which ones fall short.

    We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European countries they feel need the most work.

    • 9 min
    Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation

    Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation

    We sat down with an author of the opinion piece, Dorothy McCabe, PhD, the executive director of clinical development and medical affairs, immunology and biosimilars at Boehringer Ingelheim Pharmaceuticals and co-chair of the Biosimilars Forum education committee, to discuss what more needs to be done to combat biosimilar misinformation and how patients and physicians can help the cause.

    • 7 min
    Rathore: What Biosimilar Developers Can Learn From Application Failures

    Rathore: What Biosimilar Developers Can Learn From Application Failures

    Welcome to Not So Different, a podcast from The Center for Biosimilars®. I’m your host, Assistant Editor Skylar Jeremias.

    Biologic drug development requires complex processes to obtain desired results, and biosimilar manufacturing is no exception. However, biosimilar developers often run into complications when seeking approval from regulatory authorities. A recent study of failed applications for biosimilar approval revealed multiple reasons why biosimilar applications in the United States and Europe have been such a challenge.

    We sat down with Anurag Rathore, PhD, lead author of the study and coordinator of the Center of Excellence for Biopharmaceutical Technology in Delhi, India, to discuss the findings from this study and how biosimilar corporations can learn from them.

    • 7 min
    Byoungseo Choi on Celltrion's Biosimilar Goals For 2030

    Byoungseo Choi on Celltrion's Biosimilar Goals For 2030

    With its infliximab biosimilar, CT-P13 (Inflectra, Remsima) is undergoing trials as a possible treatment for coronavirus disease 2019 (COVID-19), Celltrion Healthcare also has ambitious plans to launch 1 new biosimilar per year through 2030.

    We sat down with Byoungseo Choi, the head of marketing for Celltrion Healthcare, to discuss exactly how this plan is going to work, the company’s current biosimilar pipeline, and its expectations for how their products will perform.

    • 8 min
    Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization

    Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization

    We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how Emory's biosimilar utilization program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.

    • 4 min
    Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins

    Dr Jing Chao Discusses Knowledge Gaps and the Future for Biosimilar Insulins

    Many physicians are wary about prescribing biosimilars, worrying that they are not as safe and effective as their reference products. Additionally, fears could be worsened as there have disturbing accounts of patients developing serious medical conditions as a result of switching insulin products.

    However, study results presented at the American Diabetes Association 80th Scientific Sessions online conference concluded that increased risks of hypo- and hyperglycemia as a result of switching from insulin degludec (iDeg) to another insulin stem from physicians administering inappropriate doses when switching entire insulin products. Investigators believe this is a consequence of physicians having a poor understanding of the pharmacodynamics and pharmacokinetics of iDeg.

    We sat down with Dr. Jing Chao, an assistant professor of medicine and metabolism, endocrinology and nutrition at the University of Washington in Seattle and one of the lead investigators of this study to discuss the f

    • 5 min

Top Podcasts In Health & Fitness

Listeners Also Subscribed To